ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

Published:2012-02-02 Issue:7 Volume:26 Page:1458-1461
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Pospisilova S, ,Gonzalez D,Malcikova J,Trbusek M,Rossi D,Kater A P,Cymbalista F,Eichhorst B,Hallek M,Döhner H,Hillmen P,van Oers M,Gribben J,Ghia P,Montserrat E,Stilgenbauer S,Zenz T

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201225.pdf

Reference30 articles.

1. Levine AJ, Oren M . The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749–758.

2. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322–3329.

3. Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 4473–4479.

4. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009; 15: 995–1004.

5. Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011; 29: 2223–2229.

Cited by 173 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence of TP53 mutations in patients with chronic lymphocytic leukemia in Iran;Asian Journal of Oncology;2024-06-25

2. Low‐burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation;The Journal of Pathology: Clinical Research;2023-11-21

3. Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region;Acta Haematologica;2023-09-26

4. A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency;Current Oncology;2022-12-25

5. Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage;Molecular Oncology;2022-12-02